Search

Displaying results 2561 - 2570 of 10000 in total
  1. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  2. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.

  3. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … different definitions of autoantibody positivity, making comparison between trials difficult; all trials involve large portions of patients also using corticosteroids, which may alter patient responses in

    Categories: Type I Interferon Receptor Antagonist
  4. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

  5. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.

  6. Drug

    Sodium cellulose phosphate

    go.drugbank.com/drugs/DB06776
    Approved

    [A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption. … Sodium cellulose phosphate is used to treat hypercalcemia and hypercalciuria. It has been used to prevent kidney stones.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Phosphatidyl serine

    go.drugbank.com/drugs/DB00144
    ApprovedNutraceutical

    PS has been investigated in a small number of double-blind placebo trials and has been shown to increase memory performance in the elderly. … PS has been shown to slow cognitive decline in animal models.

  8. Drug

    Diclofenamide

    go.drugbank.com/drugs/DB01144
    Approved

    A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.

  9. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    Severe leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients. … [L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115]

  10. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications … This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069].

    Synonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate